Compare AIRI & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRI | COCP |
|---|---|---|
| Founded | 1979 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 13.7M |
| IPO Year | 2013 | 2011 |
| Metric | AIRI | COCP |
|---|---|---|
| Price | $3.02 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 45.6K | ★ 102.3K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.39 | ★ 54.65 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,921,000.00 | $12,712,091.00 |
| Revenue This Year | $6.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.55 | $0.86 |
| 52 Week High | $4.17 | $2.19 |
| Indicator | AIRI | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 47.58 |
| Support Level | $3.01 | $1.00 |
| Resistance Level | $3.13 | $1.11 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 14.29 | 66.70 |
Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.